ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

etnb

Net Common Stock Issuance

Last Annual Value

157.57M

3-Year CAGR

247%

5-Year CAGR

12%

10-Year CAGR

Adjust for Inflation

89bio, Inc. Competitors Analysis of Net Common Stock Issuance

ETNB · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
89bio, Inc. NASDAQ:ETNB	157.57M	-31.8%	110.9%	N/A
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	8.68M	16.9%	N/A	-25.4%
Beam Therapeutics Inc. NASDAQ:BEAM	478.05M	21.0%	-8.8%	N/A
Cogent Biosciences, Inc. NASDAQ:COGT	712.00M	63.9%	79.7%	N/A
Denali Therapeutics Inc. NASDAQ:DNLI	197.38M	122.9%	N/A	N/A
ImmunityBio, Inc. NASDAQ:IBRX	400.78M	53.8%	N/A	N/A
Liquidia Corporation NASDAQ:LQDA	4.82M	-41.6%	-26.0%	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	561.72M	68.2%	255.8%	97.3%
Arcus Biosciences, Inc. NYSE:RCUS	439.00M	159.9%	14.8%	N/A
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	532.96M	60.8%	2.9%	N/A

89bio, Inc. Fair Value Envelope

ETNB · NASDAQ

Our analysis suggests that ETNB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.84, this represents a potential HIDDEN relative to our calculated worth for 89bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.84

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.